ANN ARBOR, Mich., Oct. 12, 2011 /PRNewswire/ -- Adeona
Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative
medicines for serious central nervous system diseases, announced
today that George J. Brewer, M.D.,
the Company's Senior Vice President of Research & Development,
will be a featured speaker at the 2011 International Society for
Trace Element Research in Humans Conference to be held in Belek,
Turkey, on October 16-21, 2011. Dr. Brewer is the Morton S.
and Henrietta Sellner Emeritus Professor of Human Genetics and
Internal Medicine at the University of
Michigan.
During the plenary session "Distinguished Scientist of the
World: George J. Brewer, M.D.", Dr.
Brewer will discuss the role of zinc deficiency and copper toxicity
on cognitive loss and their contributions to the current epidemic
of Alzheimer's disease. Dr. Brewer will also Co-Chair the plenary
session "Fifty Years of the Miracle Element Zinc" with Ananda S. Prasad, M.D., Ph.D., a Distinguished
Professor of Internal Medicine at Wayne State
University School of Medicine and an Adeona Scientific
Advisory Board member. During this plenary session, Dr. Brewer will
discuss zinc therapy for Wilson's disease and Alzheimer's
disease.
About International Society for Trace Element Research in
Humans
The International Society for Trace Element Research in Humans
was founded in 1984 as a non-profit corporation to: 1) encourage
and promote increased scientific and clinical research on the
causes, alleviation of suffering and the cure of trace element
disorders; 2) accumulate information about trace elements, and
promote its dissemination to scientists and physicians and other
concerned parties; and 3) educate the general public and medical
profession about the existence, diagnosis and treatment of trace
element disorders. For more information about International Society
for Trace Element Research in Humans, please visit the website at
www.isterh.com.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing
innovative medicines for the treatment of serious central nervous
system diseases. The Company's strategy is to license product
candidates that have demonstrated a certain level of clinical
efficacy and develop them to a stage that results in a significant
commercial collaboration. Adeona is developing, or has partnered
the development of, drug product candidates to treat multiple
sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and
Alzheimer's disease. The Company is currently preparing to make the
following products commercially available: reaZin™, a
prescription medical food for the dietary management of zinc
deficiency associated with Alzheimer's disease, and
wellZin™, a homeopathic over-the-counter medicine for
reducing the duration and symptoms of the common cold. Adeona also
operates Adeona Clinical Laboratory, a wholly owned clinical
reference laboratory that provides a broad array of chemistry and
microbiology diagnostic tests. For more information, please visit
Adeona's website at www.adeonapharma.com.
SOURCE Adeona Pharmaceuticals, Inc.